Compare Inovio Pharmaceuticals Inc (INO) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Monster Beverage Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Monster Beverage Corp trades at $94.95 (market cap $93.35B). The key difference: Monster Beverage Corp is far larger — about 1045.7× Inovio Pharmaceuticals Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | MNST | |
|---|---|---|
Market Cap | $89.27M | $93.35B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $99.94 |
52-Week Low | $1.05 | $58.75 |
Enterprise Value | $60.28M | $91.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Monster Beverage (MNST) trades at $95.79, down 1.75% over 24 hours but near its 52-week high of $99.53. The stock shows strong fundamentals with consistent earnings beats, revenue growth to $8.29B in 2025, and robust profitability margins. A 2-for-1 stock split announced for August 2026 reflects confidence, while technical indicators signal a bullish trend with support at $94.
Outlook remains positive driven by international expansion and product innovation, with a consensus price target of $97.83 offering modest upside. Risks include high valuation multiples and competitive pressures in the energy drink sector. Analyst sentiment is predominantly bullish, supporting a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
